KindredBio Announces Appointment of Stephen Sundlof, Former Director of FDA’s CVM, as Senior Vice President of Regulatory Affairs

SAN FRANCISCO, California. (August 22, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today that it has appointed Stephen Sundlof, DVM, PhD, former Director of Center for Veterinary Medicine at the U.S. Food and Drug Administration, as its Senior Vice President of Regulatory Affairs.

Read more

KindredBio Announces Initiation of Pivotal Clinical Study for CereKin™

CereKin™ (KIND-001), a novel oral cytokine inhibitor, is expected to be a major step forward in the treatment of dogs with arthritis.

SAN FRANCISCO, California – Kindred Biosciences, Inc. (KindredBio) announced today that it has initiated a pivotal clinical trial for CereKin™ (KIND-001) in dogs with osteoarthritis. The trial is being conducted under a protocol concurrence negotiated with the FDA and, if positive, is expected to lead to the approval of CereKin™ by 2015.

Read more

KindredBio Appoints Kevin Schultz, Former CSO of Merial, as CSO

Dr. Schultz, former Chief Scientific Officer and Global Head of R&D for Merial, joins the KindredBio team.

SAN FRANCISCO, California. (July 2, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today that it has appointed Kevin Schultz, DVM, PhD, former Chief Scientific Officer and Head of R&D for Merial, as Chief Scientific Officer and Head of R&D for KindredBio.

Read more

KindredBio Announces Protocol Concurrences from the FDA on Pivotal Studies

FDA issues the equivalent of a Special Protocol Assessment on KIND-001 and KIND-002 Pivotal Studies.

SAN FRANCISCO, California. (July 2, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today that it has received concurrences from the Center for Veterinary Medicine of the U.S. Food and Drug Administration (FDA) on its protocols for two pivotal (Phase III) field studies for KIND-001 and KIND-002. A protocol concurrence, similar to a Special Protocol Assessment for a human study, is a written commitment from the FDA that it is in agreement with the design, execution, and the analysis proposed in the protocol.

Read more

KindredBio Announces the Filing of an INAD for Laminitis in Horses

KIND-005 is expected to be a major new therapy for the treatment of laminitis in horses.

SAN FRANCISCO, California. (March 26, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today the filing of an Investigational New Animal Drug Application (INAD) with the U.S. Food and Drug Administration (FDA) for KIND-005. KIND-005 inhibits a biological pathway that plays a critical role in the pathogenesis of equine laminitis.

Read more

KindredBio Announces Filing of an Investigational New Animal Drug Application for KIND-002

KIND-002 is expected to be a major new therapy for severe cutaneous diseases in dogs​

SAN FRANCISCO, California. (February 3, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today the filing of an Investigational New Animal Drug Application (INAD) with the U.S. Food and Drug Administration (FDA) for KIND-002. KIND-002 is a potent molecule being developed for severe dermatological diseases in dogs.

Read more

KindredBio Elects Ervin Veszprémi, Former Global Head of Marketing for Novartis Animal Health, to Its Board of Directors

Highly Regarded Veterinary Marketing Executive to Join KindredBio’s Board

SAN FRANCISCO, California, (January 22, 2013) – Kindred Biosciences, Inc., (KindredBio) a biotechnology company focused on developing therapies for companion animals, today announced that Mr. Ervin Veszprémi will be joining the company’s Board of Directors.

Read more